Please or Register to create posts and topics.

Boohoo founders Medusa 19 COVID-19 rapid test under fire from professors as importance of MHRA approvals highlighted

A rapid COVID-19 saliva-based test from a company called Medusa 19 has come under fire over its accuracy. Medusa 19 is a company that was created by Boohoo founders Richard Hughes and Mahmud Kamani.

The lateral test promises to provide results in 10 minutes by using a person's saliva to see if they have had the virus before or currently have it.

According to the FT, the test is sold for £29.99 and needs administration by a doctor or nurse.

However with just a 92 percent specificity rate from preliminary trials, the Medusa 19 has come under serious criticism.

Jon Deeks, a professor from Birmingham University said the specificity of 'this test [Medusa 19] is appalling compared to PT-PCR and other antibody tests'.

Richard Tedder from the Imperial College London added that a CE marking tells you a test is 'barely adequate'.

Tedder further went on to say that its a 'distortion of the truth' for the respective test to tell if you have COVID-19', adding that tests such as these are 'really dangerous'.

The strong views from the professors quoted by the FT indicate the importance of tests meeting the MHRA specificity targets; 98% for rapid antibody tests and 99% for rapid antigen tests.

Earlier in the week, the UK Rapid Test Consortrium noted its tests at-home antibody test has shown specificity of 99.56% as part of a brochure that highlighted the 'invaluable role' that its 'quick, easy' antibody test will play in overcoming COVID-19 - including in the measuring of vaccine success.

Expecting a rocket when this MHRA RNS lands as there is nothing like it on the market, everyone will want it out of curiosity anyway.

Hey, profit awaits! Free Sharebuyers Newsletter

Receive the hottest share tips and must-know investing information you can profit from.